Who is sponsoring NCT00613964?

NCT00613964 is sponsored by Nara Medical University.

What condition does NCT00613964 study?

NCT00613964 studies Heart Failure, Renal Failure.

What drugs are being tested in NCT00613964?

Interventions: Carperitide heart failure therapy, Standard heart failure therapy.

What is the status of NCT00613964?

NCT00613964 is currently TERMINATED.

Last reviewed 2011-07-20 · How we verify

The Effects of Carperitide on Short and Long-term Prognosis in Patients With Both Cardiac and Renal Failure

NCT00613964 Phase 4 TERMINATED

Carperitide (alpha-human atrial natriuretic peptide) improves systemic hemodynamics in patients with heart failure through a vasodilatory action, a natriuretic action, and inhibition of the renin-angiotensin-aldosterone system and has been widely-used in Japan. However, a paucity of report is available on the effects of carperitide on short and long-term prognosis in patients with both cardiac and renal failure. The purpose of this study is to evaluate the effects of carperitide therapy on short and long-term prognosis in patients with both cardiac and renal failure, in comparison with standard therapy.

Details

Lead sponsor	Nara Medical University
Phase	Phase 4
Status	TERMINATED
Enrolment	200
Start date	2009-05
Completion	2013-05

Conditions

Heart Failure
Renal Failure

Interventions

Carperitide heart failure therapy
Standard heart failure therapy

Primary outcomes

Unexpected rehospitalization for cardiovascular events, uremic symptom, initiation of maintenance dialysis, and kidney transplantation — at 6 months and 2 years

Countries

Japan